IBDEI02A ; ; 01-AUG-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,5256,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5256,1,3,0)
;;=3^Adrenocortical Insufficiency,Primary
;;^UTILITY(U,$J,358.3,5256,1,4,0)
;;=4^E27.1
;;^UTILITY(U,$J,358.3,5256,2)
;;=^5002740
;;^UTILITY(U,$J,358.3,5257,0)
;;=E27.49^^34^292^13
;;^UTILITY(U,$J,358.3,5257,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5257,1,3,0)
;;=3^Adrenocortical Insufficiency,Other
;;^UTILITY(U,$J,358.3,5257,1,4,0)
;;=4^E27.49
;;^UTILITY(U,$J,358.3,5257,2)
;;=^5002743
;;^UTILITY(U,$J,358.3,5258,0)
;;=E27.3^^34^292^12
;;^UTILITY(U,$J,358.3,5258,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5258,1,3,0)
;;=3^Adrenocortical Insufficiency,Drug-Induced
;;^UTILITY(U,$J,358.3,5258,1,4,0)
;;=4^E27.3
;;^UTILITY(U,$J,358.3,5258,2)
;;=^5002741
;;^UTILITY(U,$J,358.3,5259,0)
;;=E27.5^^34^292^16
;;^UTILITY(U,$J,358.3,5259,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5259,1,3,0)
;;=3^Adrenomedullary Hyperfunction
;;^UTILITY(U,$J,358.3,5259,1,4,0)
;;=4^E27.5
;;^UTILITY(U,$J,358.3,5259,2)
;;=^5002744
;;^UTILITY(U,$J,358.3,5260,0)
;;=N18.1^^34^292^43
;;^UTILITY(U,$J,358.3,5260,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5260,1,3,0)
;;=3^CKD,Stage 1
;;^UTILITY(U,$J,358.3,5260,1,4,0)
;;=4^N18.1
;;^UTILITY(U,$J,358.3,5260,2)
;;=^5015602
;;^UTILITY(U,$J,358.3,5261,0)
;;=N18.2^^34^292^44
;;^UTILITY(U,$J,358.3,5261,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5261,1,3,0)
;;=3^CKD,Stage 2
;;^UTILITY(U,$J,358.3,5261,1,4,0)
;;=4^N18.2
;;^UTILITY(U,$J,358.3,5261,2)
;;=^5015603
;;^UTILITY(U,$J,358.3,5262,0)
;;=N18.31^^34^292^46
;;^UTILITY(U,$J,358.3,5262,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5262,1,3,0)
;;=3^CKD,Stage 3A
;;^UTILITY(U,$J,358.3,5262,1,4,0)
;;=4^N18.31
;;^UTILITY(U,$J,358.3,5262,2)
;;=^5159287
;;^UTILITY(U,$J,358.3,5263,0)
;;=N18.32^^34^292^47
;;^UTILITY(U,$J,358.3,5263,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5263,1,3,0)
;;=3^CKD,Stage 3B
;;^UTILITY(U,$J,358.3,5263,1,4,0)
;;=4^N18.32
;;^UTILITY(U,$J,358.3,5263,2)
;;=^5159288
;;^UTILITY(U,$J,358.3,5264,0)
;;=N18.30^^34^292^45
;;^UTILITY(U,$J,358.3,5264,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5264,1,3,0)
;;=3^CKD,Stage 3,Unspec
;;^UTILITY(U,$J,358.3,5264,1,4,0)
;;=4^N18.30
;;^UTILITY(U,$J,358.3,5264,2)
;;=^5159286
;;^UTILITY(U,$J,358.3,5265,0)
;;=N18.4^^34^292^48
;;^UTILITY(U,$J,358.3,5265,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5265,1,3,0)
;;=3^CKD,Stage 4
;;^UTILITY(U,$J,358.3,5265,1,4,0)
;;=4^N18.4
;;^UTILITY(U,$J,358.3,5265,2)
;;=^5015605
;;^UTILITY(U,$J,358.3,5266,0)
;;=N18.5^^34^292^49
;;^UTILITY(U,$J,358.3,5266,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5266,1,3,0)
;;=3^CKD,Stage 5
;;^UTILITY(U,$J,358.3,5266,1,4,0)
;;=4^N18.5
;;^UTILITY(U,$J,358.3,5266,2)
;;=^5015606
;;^UTILITY(U,$J,358.3,5267,0)
;;=E11.42^^34^292^69
;;^UTILITY(U,$J,358.3,5267,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5267,1,3,0)
;;=3^Diabetes Type 2 w/ Peripheral Neuropathy
;;^UTILITY(U,$J,358.3,5267,1,4,0)
;;=4^E11.42
;;^UTILITY(U,$J,358.3,5267,2)
;;=^5002646
;;^UTILITY(U,$J,358.3,5268,0)
;;=E11.43^^34^292^57
;;^UTILITY(U,$J,358.3,5268,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5268,1,3,0)
;;=3^Diabetes Type 2 w/ Autonomic Neuropathy
;;^UTILITY(U,$J,358.3,5268,1,4,0)
;;=4^E11.43
;;^UTILITY(U,$J,358.3,5268,2)
;;=^5002647
;;^UTILITY(U,$J,358.3,5269,0)
;;=E11.52^^34^292^68
;;^UTILITY(U,$J,358.3,5269,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5269,1,3,0)
;;=3^Diabetes Type 2 w/ Peripheral Angiopathy w/ Gangrene
;;^UTILITY(U,$J,358.3,5269,1,4,0)
;;=4^E11.52
;;^UTILITY(U,$J,358.3,5269,2)
;;=^5002651
;;^UTILITY(U,$J,358.3,5270,0)
;;=Z79.84^^34^292^145
;;^UTILITY(U,$J,358.3,5270,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5270,1,3,0)
;;=3^Long Term (Current) Use of Oral Hypoglycemics
;;^UTILITY(U,$J,358.3,5270,1,4,0)
;;=4^Z79.84
;;^UTILITY(U,$J,358.3,5270,2)
;;=^5140432
;;^UTILITY(U,$J,358.3,5271,0)
;;=Z79.899^^34^292^146
;;^UTILITY(U,$J,358.3,5271,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5271,1,3,0)
;;=3^Long Term (Current) Use of Oth Drug Therapy
;;^UTILITY(U,$J,358.3,5271,1,4,0)
;;=4^Z79.899
;;^UTILITY(U,$J,358.3,5271,2)
;;=^5063343
;;^UTILITY(U,$J,358.3,5272,0)
;;=Z79.01^^34^292^140
;;^UTILITY(U,$J,358.3,5272,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5272,1,3,0)
;;=3^Long Term (Current) Use of Anticoagulants
;;^UTILITY(U,$J,358.3,5272,1,4,0)
;;=4^Z79.01
;;^UTILITY(U,$J,358.3,5272,2)
;;=^5063330
;;^UTILITY(U,$J,358.3,5273,0)
;;=Z79.02^^34^292^141
;;^UTILITY(U,$J,358.3,5273,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5273,1,3,0)
;;=3^Long Term (Current) Use of Antithrombotics/Antiplatelets
;;^UTILITY(U,$J,358.3,5273,1,4,0)
;;=4^Z79.02
;;^UTILITY(U,$J,358.3,5273,2)
;;=^5063331
;;^UTILITY(U,$J,358.3,5274,0)
;;=Z79.82^^34^292^142
;;^UTILITY(U,$J,358.3,5274,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5274,1,3,0)
;;=3^Long Term (Current) Use of Aspirin
;;^UTILITY(U,$J,358.3,5274,1,4,0)
;;=4^Z79.82
;;^UTILITY(U,$J,358.3,5274,2)
;;=^5063340
;;^UTILITY(U,$J,358.3,5275,0)
;;=Z79.51^^34^292^143
;;^UTILITY(U,$J,358.3,5275,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5275,1,3,0)
;;=3^Long Term (Current) Use of Inhaled Steroids
;;^UTILITY(U,$J,358.3,5275,1,4,0)
;;=4^Z79.51
;;^UTILITY(U,$J,358.3,5275,2)
;;=^5063335
;;^UTILITY(U,$J,358.3,5276,0)
;;=Z79.52^^34^292^147
;;^UTILITY(U,$J,358.3,5276,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5276,1,3,0)
;;=3^Long Term (Current) Use of Systemic Steroids
;;^UTILITY(U,$J,358.3,5276,1,4,0)
;;=4^Z79.52
;;^UTILITY(U,$J,358.3,5276,2)
;;=^5063336
;;^UTILITY(U,$J,358.3,5277,0)
;;=E22.8^^34^292^200
;;^UTILITY(U,$J,358.3,5277,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5277,1,3,0)
;;=3^Pituitary Hyperfunction,Other
;;^UTILITY(U,$J,358.3,5277,1,4,0)
;;=4^E22.8
;;^UTILITY(U,$J,358.3,5277,2)
;;=^5002719
;;^UTILITY(U,$J,358.3,5278,0)
;;=E22.2^^34^292^221
;;^UTILITY(U,$J,358.3,5278,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5278,1,3,0)
;;=3^SIADH
;;^UTILITY(U,$J,358.3,5278,1,4,0)
;;=4^E22.2
;;^UTILITY(U,$J,358.3,5278,2)
;;=^5002718
;;^UTILITY(U,$J,358.3,5279,0)
;;=T45.1X5A^^34^292^20
;;^UTILITY(U,$J,358.3,5279,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5279,1,3,0)
;;=3^Adverse Effect,Antineoplastic/Immunosuppressive,Init Enctr
;;^UTILITY(U,$J,358.3,5279,1,4,0)
;;=4^T45.1X5A
;;^UTILITY(U,$J,358.3,5279,2)
;;=^5051026
;;^UTILITY(U,$J,358.3,5280,0)
;;=T45.1X5D^^34^292^21
;;^UTILITY(U,$J,358.3,5280,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5280,1,3,0)
;;=3^Adverse Effect,Antineoplastic/Immunosuppressive,Subsq
;;^UTILITY(U,$J,358.3,5280,1,4,0)
;;=4^T45.1X5D
;;^UTILITY(U,$J,358.3,5280,2)
;;=^5051027
;;^UTILITY(U,$J,358.3,5281,0)
;;=T45.1X5S^^34^292^22
;;^UTILITY(U,$J,358.3,5281,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5281,1,3,0)
;;=3^Adverse Effect,Antineoplastic/Immunosuppressive,Sequela
;;^UTILITY(U,$J,358.3,5281,1,4,0)
;;=4^T45.1X5S
;;^UTILITY(U,$J,358.3,5281,2)
;;=^5051028
;;^UTILITY(U,$J,358.3,5282,0)
;;=T46.2X5A^^34^292^17
;;^UTILITY(U,$J,358.3,5282,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5282,1,3,0)
;;=3^Adverse Effect,Antidysrhthmic,Init Encntr
;;^UTILITY(U,$J,358.3,5282,1,4,0)
;;=4^T46.2X5A
;;^UTILITY(U,$J,358.3,5282,2)
;;=^5051296
;;^UTILITY(U,$J,358.3,5283,0)
;;=T46.2X5D^^34^292^19
;;^UTILITY(U,$J,358.3,5283,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5283,1,3,0)
;;=3^Adverse Effect,Antidysrhthmic,Subsq
;;^UTILITY(U,$J,358.3,5283,1,4,0)
;;=4^T46.2X5D
;;^UTILITY(U,$J,358.3,5283,2)
;;=^5051297
;;^UTILITY(U,$J,358.3,5284,0)
;;=T46.2X5S^^34^292^18
;;^UTILITY(U,$J,358.3,5284,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5284,1,3,0)
;;=3^Adverse Effect,Antidysrhthmic,Sequela
;;^UTILITY(U,$J,358.3,5284,1,4,0)
;;=4^T46.2X5S
;;^UTILITY(U,$J,358.3,5284,2)
;;=^5051298
;;^UTILITY(U,$J,358.3,5285,0)
;;=N91.0^^34^292^24
;;^UTILITY(U,$J,358.3,5285,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5285,1,3,0)
;;=3^Amenorrhea,Primary
;;^UTILITY(U,$J,358.3,5285,1,4,0)
;;=4^N91.0
;;^UTILITY(U,$J,358.3,5285,2)
;;=^5015902
;;^UTILITY(U,$J,358.3,5286,0)
;;=N91.1^^34^292^25
;;^UTILITY(U,$J,358.3,5286,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5286,1,3,0)
;;=3^Amenorrhea,Secondary
;;^UTILITY(U,$J,358.3,5286,1,4,0)
;;=4^N91.1
;;^UTILITY(U,$J,358.3,5286,2)
;;=^5015903
;;^UTILITY(U,$J,358.3,5287,0)
;;=N91.2^^34^292^26
;;^UTILITY(U,$J,358.3,5287,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5287,1,3,0)
;;=3^Amenorrhea,Unspec
;;^UTILITY(U,$J,358.3,5287,1,4,0)
;;=4^N91.2
;;^UTILITY(U,$J,358.3,5287,2)
;;=^5015904
;;^UTILITY(U,$J,358.3,5288,0)
;;=Z98.84^^34^292^33
;;^UTILITY(U,$J,358.3,5288,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5288,1,3,0)
;;=3^Bariatric Surgery Status
;;^UTILITY(U,$J,358.3,5288,1,4,0)
;;=4^Z98.84
;;^UTILITY(U,$J,358.3,5288,2)
;;=^5063749
;;^UTILITY(U,$J,358.3,5289,0)
;;=N18.6^^34^292^50
;;^UTILITY(U,$J,358.3,5289,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5289,1,3,0)
;;=3^CKD,Stage 6 (ESRD)
;;^UTILITY(U,$J,358.3,5289,1,4,0)
;;=4^N18.6
;;^UTILITY(U,$J,358.3,5289,2)
;;=^303986
;;^UTILITY(U,$J,358.3,5290,0)
;;=E25.0^^34^292^11
;;^UTILITY(U,$J,358.3,5290,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5290,1,3,0)
;;=3^Adrenal Hyperplasia,Congenital
;;^UTILITY(U,$J,358.3,5290,1,4,0)
;;=4^E25.0
;;^UTILITY(U,$J,358.3,5290,2)
;;=^5002732
;;^UTILITY(U,$J,358.3,5291,0)
;;=E11.69^^34^292^67
;;^UTILITY(U,$J,358.3,5291,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5291,1,3,0)
;;=3^Diabetes Type 2 w/ Oth Specified Complication
;;^UTILITY(U,$J,358.3,5291,1,4,0)
;;=4^E11.69
;;^UTILITY(U,$J,358.3,5291,2)
;;=^5002664
;;^UTILITY(U,$J,358.3,5292,0)
;;=F64.0^^34^292^76
;;^UTILITY(U,$J,358.3,5292,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5292,1,3,0)
;;=3^Gender Dysphoria
;;^UTILITY(U,$J,358.3,5292,1,4,0)
;;=4^F64.0
;;^UTILITY(U,$J,358.3,5292,2)
;;=^121404
;;^UTILITY(U,$J,358.3,5293,0)
;;=E05.01^^34^292^78
;;^UTILITY(U,$J,358.3,5293,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5293,1,3,0)
;;=3^Graves Disease w/ Thyrotoxic Crisis/Storm
;;^UTILITY(U,$J,358.3,5293,1,4,0)
;;=4^E05.01
;;^UTILITY(U,$J,358.3,5293,2)
;;=^5002482
;;^UTILITY(U,$J,358.3,5294,0)
;;=E28.1^^34^292^100
;;^UTILITY(U,$J,358.3,5294,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5294,1,3,0)
;;=3^Hyperandrogenism
;;^UTILITY(U,$J,358.3,5294,1,4,0)
;;=4^E28.1
;;^UTILITY(U,$J,358.3,5294,2)
;;=^5002748
;;^UTILITY(U,$J,358.3,5295,0)
;;=E87.5^^34^292^103
;;^UTILITY(U,$J,358.3,5295,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5295,1,3,0)
;;=3^Hyperkalemia
;;^UTILITY(U,$J,358.3,5295,1,4,0)
;;=4^E87.5
;;^UTILITY(U,$J,358.3,5295,2)
;;=^60041
;;^UTILITY(U,$J,358.3,5296,0)
;;=I50.1^^34^292^90
;;^UTILITY(U,$J,358.3,5296,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5296,1,3,0)
;;=3^Heart Failure,Left Ventricular
;;^UTILITY(U,$J,358.3,5296,1,4,0)
;;=4^I50.1
;;^UTILITY(U,$J,358.3,5296,2)
;;=^5007238
;;^UTILITY(U,$J,358.3,5297,0)
;;=I50.21^^34^292^95
;;^UTILITY(U,$J,358.3,5297,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5297,1,3,0)
;;=3^Heart Failure,Systolic,Acute
;;^UTILITY(U,$J,358.3,5297,1,4,0)
;;=4^I50.21
;;^UTILITY(U,$J,358.3,5297,2)
;;=^5007240
;;^UTILITY(U,$J,358.3,5298,0)
;;=I50.22^^34^292^97
;;^UTILITY(U,$J,358.3,5298,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5298,1,3,0)
;;=3^Heart Failure,Systolic,Chronic
;;^UTILITY(U,$J,358.3,5298,1,4,0)
;;=4^I50.22
;;^UTILITY(U,$J,358.3,5298,2)
;;=^5007241
;;^UTILITY(U,$J,358.3,5299,0)
;;=I50.23^^34^292^96
;;^UTILITY(U,$J,358.3,5299,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5299,1,3,0)
;;=3^Heart Failure,Systolic,Acute on Chronic
;;^UTILITY(U,$J,358.3,5299,1,4,0)
;;=4^I50.23
;;^UTILITY(U,$J,358.3,5299,2)
;;=^5007242
;;^UTILITY(U,$J,358.3,5300,0)
;;=I50.31^^34^292^85
;;^UTILITY(U,$J,358.3,5300,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5300,1,3,0)
;;=3^Heart Failure,Diastolic,Acute
;;^UTILITY(U,$J,358.3,5300,1,4,0)
;;=4^I50.31
;;^UTILITY(U,$J,358.3,5300,2)
;;=^5007244
;;^UTILITY(U,$J,358.3,5301,0)
;;=I50.32^^34^292^87
;;^UTILITY(U,$J,358.3,5301,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5301,1,3,0)
;;=3^Heart Failure,Diastolic,Chronic
;;^UTILITY(U,$J,358.3,5301,1,4,0)
;;=4^I50.32
;;^UTILITY(U,$J,358.3,5301,2)
;;=^5007245
;;^UTILITY(U,$J,358.3,5302,0)
;;=I50.33^^34^292^86
;;^UTILITY(U,$J,358.3,5302,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5302,1,3,0)
;;=3^Heart Failure,Diastolic,Acute on Chronic
;;^UTILITY(U,$J,358.3,5302,1,4,0)
;;=4^I50.33
;;^UTILITY(U,$J,358.3,5302,2)
;;=^5007246
;;^UTILITY(U,$J,358.3,5303,0)
;;=I50.41^^34^292^82
;;^UTILITY(U,$J,358.3,5303,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5303,1,3,0)
;;=3^Heart Failure,Combined,Acute
;;^UTILITY(U,$J,358.3,5303,1,4,0)
;;=4^I50.41
;;^UTILITY(U,$J,358.3,5303,2)
;;=^5007248
;;^UTILITY(U,$J,358.3,5304,0)
;;=I50.42^^34^292^84
;;^UTILITY(U,$J,358.3,5304,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5304,1,3,0)
;;=3^Heart Failure,Combined,Chronic
;;^UTILITY(U,$J,358.3,5304,1,4,0)
;;=4^I50.42
;;^UTILITY(U,$J,358.3,5304,2)
;;=^5007249
;;^UTILITY(U,$J,358.3,5305,0)
;;=I50.43^^34^292^83
;;^UTILITY(U,$J,358.3,5305,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5305,1,3,0)
;;=3^Heart Failure,Combined,Acute on Chronic
;;^UTILITY(U,$J,358.3,5305,1,4,0)
;;=4^I50.43
;;^UTILITY(U,$J,358.3,5305,2)
;;=^5007250
;;^UTILITY(U,$J,358.3,5306,0)
;;=I50.811^^34^292^92
;;^UTILITY(U,$J,358.3,5306,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5306,1,3,0)
;;=3^Heart Failure,Right,Acute
;;^UTILITY(U,$J,358.3,5306,1,4,0)
;;=4^I50.811
;;^UTILITY(U,$J,358.3,5306,2)
;;=^5151385
;;^UTILITY(U,$J,358.3,5307,0)
;;=I50.812^^34^292^94
;;^UTILITY(U,$J,358.3,5307,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5307,1,3,0)
;;=3^Heart Failure,Right,Chronic
;;^UTILITY(U,$J,358.3,5307,1,4,0)
;;=4^I50.812
;;^UTILITY(U,$J,358.3,5307,2)
;;=^5151386
;;^UTILITY(U,$J,358.3,5308,0)
;;=I50.813^^34^292^93
;;^UTILITY(U,$J,358.3,5308,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5308,1,3,0)
;;=3^Heart Failure,Right,Acute on Chronic
;;^UTILITY(U,$J,358.3,5308,1,4,0)
;;=4^I50.813
;;^UTILITY(U,$J,358.3,5308,2)
;;=^5151387
;;^UTILITY(U,$J,358.3,5309,0)
;;=I50.814^^34^292^91
;;^UTILITY(U,$J,358.3,5309,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5309,1,3,0)
;;=3^Heart Failure,Right due to Left
;;^UTILITY(U,$J,358.3,5309,1,4,0)
;;=4^I50.814
;;^UTILITY(U,$J,358.3,5309,2)
;;=^5151388
;;^UTILITY(U,$J,358.3,5310,0)
;;=I50.82^^34^292^81
;;^UTILITY(U,$J,358.3,5310,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5310,1,3,0)
;;=3^Heart Failure,Biventricular
;;^UTILITY(U,$J,358.3,5310,1,4,0)
;;=4^I50.82
;;^UTILITY(U,$J,358.3,5310,2)
;;=^5151389
;;^UTILITY(U,$J,358.3,5311,0)
;;=I50.83^^34^292^89
;;^UTILITY(U,$J,358.3,5311,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5311,1,3,0)
;;=3^Heart Failure,High Output
;;^UTILITY(U,$J,358.3,5311,1,4,0)
;;=4^I50.83
;;^UTILITY(U,$J,358.3,5311,2)
;;=^5151390
;;^UTILITY(U,$J,358.3,5312,0)
;;=I50.84^^34^292^88
;;^UTILITY(U,$J,358.3,5312,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5312,1,3,0)
;;=3^Heart Failure,End Stage
;;^UTILITY(U,$J,358.3,5312,1,4,0)
;;=4^I50.84
;;^UTILITY(U,$J,358.3,5312,2)
;;=^5151391
;;^UTILITY(U,$J,358.3,5313,0)
;;=L68.0^^34^292^98
;;^UTILITY(U,$J,358.3,5313,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5313,1,3,0)
;;=3^Hirsutism
;;^UTILITY(U,$J,358.3,5313,1,4,0)
;;=4^L68.0
;;^UTILITY(U,$J,358.3,5313,2)
;;=^5009262
;;^UTILITY(U,$J,358.3,5314,0)
;;=I11.0^^34^292^117
;;^UTILITY(U,$J,358.3,5314,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5314,1,3,0)
;;=3^Hypertensive Hrt Disease w/ Hrt Failure
;;^UTILITY(U,$J,358.3,5314,1,4,0)
;;=4^I11.0
;;^UTILITY(U,$J,358.3,5314,2)
;;=^5007063
;;^UTILITY(U,$J,358.3,5315,0)
;;=I11.9^^34^292^118
;;^UTILITY(U,$J,358.3,5315,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5315,1,3,0)
;;=3^Hypertensive Hrt Disease w/o Hrt Failure
;;^UTILITY(U,$J,358.3,5315,1,4,0)
;;=4^I11.9
;;^UTILITY(U,$J,358.3,5315,2)
;;=^5007064
;;^UTILITY(U,$J,358.3,5316,0)
;;=I12.0^^34^292^120
;;^UTILITY(U,$J,358.3,5316,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5316,1,3,0)
;;=3^Hypertensive Kidney Disease w/ CKD5/ESRD
;;^UTILITY(U,$J,358.3,5316,1,4,0)
;;=4^I12.0
;;^UTILITY(U,$J,358.3,5316,2)
;;=^5007065
;;^UTILITY(U,$J,358.3,5317,0)
;;=I12.9^^34^292^119
;;^UTILITY(U,$J,358.3,5317,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5317,1,3,0)
;;=3^Hypertensive Kidney Disease w/ CKD1-CKD4
;;^UTILITY(U,$J,358.3,5317,1,4,0)
;;=4^I12.9
;;^UTILITY(U,$J,358.3,5317,2)
;;=^5007066
;;^UTILITY(U,$J,358.3,5318,0)
;;=I13.0^^34^292^113
;;^UTILITY(U,$J,358.3,5318,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5318,1,3,0)
;;=3^Hypertensive Hrt & Kidney Disease w/ CKD1-CKD4
;;^UTILITY(U,$J,358.3,5318,1,4,0)
;;=4^I13.0
;;^UTILITY(U,$J,358.3,5318,2)
;;=^5007067
;;^UTILITY(U,$J,358.3,5319,0)
;;=I13.10^^34^292^115
;;^UTILITY(U,$J,358.3,5319,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5319,1,3,0)
;;=3^Hypertensive Hrt Diseas w/o CHF w/ CKD1-CKD4
;;^UTILITY(U,$J,358.3,5319,1,4,0)
;;=4^I13.10
;;^UTILITY(U,$J,358.3,5319,2)
;;=^5007068
;;^UTILITY(U,$J,358.3,5320,0)
;;=I13.11^^34^292^116
;;^UTILITY(U,$J,358.3,5320,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5320,1,3,0)
;;=3^Hypertensive Hrt Diseas w/o CHF w/ CKD5/ESRD
;;^UTILITY(U,$J,358.3,5320,1,4,0)
;;=4^I13.11
;;^UTILITY(U,$J,358.3,5320,2)
;;=^5007069
;;^UTILITY(U,$J,358.3,5321,0)
;;=I13.2^^34^292^114
;;^UTILITY(U,$J,358.3,5321,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5321,1,3,0)
;;=3^Hypertensive Hrt & Kidney Disease w/ CKD5/ESRD
;;^UTILITY(U,$J,358.3,5321,1,4,0)
;;=4^I13.2
;;^UTILITY(U,$J,358.3,5321,2)
;;=^5007070
;;^UTILITY(U,$J,358.3,5322,0)
;;=E87.6^^34^292^126
;;^UTILITY(U,$J,358.3,5322,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5322,1,3,0)
;;=3^Hypokalemia
;;^UTILITY(U,$J,358.3,5322,1,4,0)
;;=4^E87.6
;;^UTILITY(U,$J,358.3,5322,2)
;;=^60610
;;^UTILITY(U,$J,358.3,5323,0)
;;=E87.1^^34^292^127
;;^UTILITY(U,$J,358.3,5323,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5323,1,3,0)
;;=3^Hyponatremia
;;^UTILITY(U,$J,358.3,5323,1,4,0)
;;=4^E87.1
;;^UTILITY(U,$J,358.3,5323,2)
;;=^5003019
;;^UTILITY(U,$J,358.3,5324,0)
;;=E23.6^^34^292^128
;;^UTILITY(U,$J,358.3,5324,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5324,1,3,0)
;;=3^Hypophysitis
;;^UTILITY(U,$J,358.3,5324,1,4,0)
;;=4^E23.6
;;^UTILITY(U,$J,358.3,5324,2)
;;=^5002723
;;^UTILITY(U,$J,358.3,5325,0)
;;=Q98.0^^34^292^136
;;^UTILITY(U,$J,358.3,5325,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,5325,1,3,0)
;;=3^Klinefelter Syndrome,Karyotype 47,XXY
;;^UTILITY(U,$J,358.3,5325,1,4,0)
;;=4^Q98.0
;;^UTILITY(U,$J,358.3,5325,2)
;;=^5019149
;;^UTILITY(U,$J,358.3,5326,0)
;;=Q98.1^^34^292^137
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI02A 19781 printed Sep 23, 2025@19:16:12 Page 2
IBDEI02A ; ; 01-AUG-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,5256,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,5256,1,3,0)
+4 ;;=3^Adrenocortical Insufficiency,Primary
+5 ;;^UTILITY(U,$J,358.3,5256,1,4,0)
+6 ;;=4^E27.1
+7 ;;^UTILITY(U,$J,358.3,5256,2)
+8 ;;=^5002740
+9 ;;^UTILITY(U,$J,358.3,5257,0)
+10 ;;=E27.49^^34^292^13
+11 ;;^UTILITY(U,$J,358.3,5257,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,5257,1,3,0)
+14 ;;=3^Adrenocortical Insufficiency,Other
+15 ;;^UTILITY(U,$J,358.3,5257,1,4,0)
+16 ;;=4^E27.49
+17 ;;^UTILITY(U,$J,358.3,5257,2)
+18 ;;=^5002743
+19 ;;^UTILITY(U,$J,358.3,5258,0)
+20 ;;=E27.3^^34^292^12
+21 ;;^UTILITY(U,$J,358.3,5258,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,5258,1,3,0)
+24 ;;=3^Adrenocortical Insufficiency,Drug-Induced
+25 ;;^UTILITY(U,$J,358.3,5258,1,4,0)
+26 ;;=4^E27.3
+27 ;;^UTILITY(U,$J,358.3,5258,2)
+28 ;;=^5002741
+29 ;;^UTILITY(U,$J,358.3,5259,0)
+30 ;;=E27.5^^34^292^16
+31 ;;^UTILITY(U,$J,358.3,5259,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,5259,1,3,0)
+34 ;;=3^Adrenomedullary Hyperfunction
+35 ;;^UTILITY(U,$J,358.3,5259,1,4,0)
+36 ;;=4^E27.5
+37 ;;^UTILITY(U,$J,358.3,5259,2)
+38 ;;=^5002744
+39 ;;^UTILITY(U,$J,358.3,5260,0)
+40 ;;=N18.1^^34^292^43
+41 ;;^UTILITY(U,$J,358.3,5260,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,5260,1,3,0)
+44 ;;=3^CKD,Stage 1
+45 ;;^UTILITY(U,$J,358.3,5260,1,4,0)
+46 ;;=4^N18.1
+47 ;;^UTILITY(U,$J,358.3,5260,2)
+48 ;;=^5015602
+49 ;;^UTILITY(U,$J,358.3,5261,0)
+50 ;;=N18.2^^34^292^44
+51 ;;^UTILITY(U,$J,358.3,5261,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,5261,1,3,0)
+54 ;;=3^CKD,Stage 2
+55 ;;^UTILITY(U,$J,358.3,5261,1,4,0)
+56 ;;=4^N18.2
+57 ;;^UTILITY(U,$J,358.3,5261,2)
+58 ;;=^5015603
+59 ;;^UTILITY(U,$J,358.3,5262,0)
+60 ;;=N18.31^^34^292^46
+61 ;;^UTILITY(U,$J,358.3,5262,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,5262,1,3,0)
+64 ;;=3^CKD,Stage 3A
+65 ;;^UTILITY(U,$J,358.3,5262,1,4,0)
+66 ;;=4^N18.31
+67 ;;^UTILITY(U,$J,358.3,5262,2)
+68 ;;=^5159287
+69 ;;^UTILITY(U,$J,358.3,5263,0)
+70 ;;=N18.32^^34^292^47
+71 ;;^UTILITY(U,$J,358.3,5263,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,5263,1,3,0)
+74 ;;=3^CKD,Stage 3B
+75 ;;^UTILITY(U,$J,358.3,5263,1,4,0)
+76 ;;=4^N18.32
+77 ;;^UTILITY(U,$J,358.3,5263,2)
+78 ;;=^5159288
+79 ;;^UTILITY(U,$J,358.3,5264,0)
+80 ;;=N18.30^^34^292^45
+81 ;;^UTILITY(U,$J,358.3,5264,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,5264,1,3,0)
+84 ;;=3^CKD,Stage 3,Unspec
+85 ;;^UTILITY(U,$J,358.3,5264,1,4,0)
+86 ;;=4^N18.30
+87 ;;^UTILITY(U,$J,358.3,5264,2)
+88 ;;=^5159286
+89 ;;^UTILITY(U,$J,358.3,5265,0)
+90 ;;=N18.4^^34^292^48
+91 ;;^UTILITY(U,$J,358.3,5265,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,5265,1,3,0)
+94 ;;=3^CKD,Stage 4
+95 ;;^UTILITY(U,$J,358.3,5265,1,4,0)
+96 ;;=4^N18.4
+97 ;;^UTILITY(U,$J,358.3,5265,2)
+98 ;;=^5015605
+99 ;;^UTILITY(U,$J,358.3,5266,0)
+100 ;;=N18.5^^34^292^49
+101 ;;^UTILITY(U,$J,358.3,5266,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,5266,1,3,0)
+104 ;;=3^CKD,Stage 5
+105 ;;^UTILITY(U,$J,358.3,5266,1,4,0)
+106 ;;=4^N18.5
+107 ;;^UTILITY(U,$J,358.3,5266,2)
+108 ;;=^5015606
+109 ;;^UTILITY(U,$J,358.3,5267,0)
+110 ;;=E11.42^^34^292^69
+111 ;;^UTILITY(U,$J,358.3,5267,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,5267,1,3,0)
+114 ;;=3^Diabetes Type 2 w/ Peripheral Neuropathy
+115 ;;^UTILITY(U,$J,358.3,5267,1,4,0)
+116 ;;=4^E11.42
+117 ;;^UTILITY(U,$J,358.3,5267,2)
+118 ;;=^5002646
+119 ;;^UTILITY(U,$J,358.3,5268,0)
+120 ;;=E11.43^^34^292^57
+121 ;;^UTILITY(U,$J,358.3,5268,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,5268,1,3,0)
+124 ;;=3^Diabetes Type 2 w/ Autonomic Neuropathy
+125 ;;^UTILITY(U,$J,358.3,5268,1,4,0)
+126 ;;=4^E11.43
+127 ;;^UTILITY(U,$J,358.3,5268,2)
+128 ;;=^5002647
+129 ;;^UTILITY(U,$J,358.3,5269,0)
+130 ;;=E11.52^^34^292^68
+131 ;;^UTILITY(U,$J,358.3,5269,1,0)
+132 ;;=^358.31IA^4^2
+133 ;;^UTILITY(U,$J,358.3,5269,1,3,0)
+134 ;;=3^Diabetes Type 2 w/ Peripheral Angiopathy w/ Gangrene
+135 ;;^UTILITY(U,$J,358.3,5269,1,4,0)
+136 ;;=4^E11.52
+137 ;;^UTILITY(U,$J,358.3,5269,2)
+138 ;;=^5002651
+139 ;;^UTILITY(U,$J,358.3,5270,0)
+140 ;;=Z79.84^^34^292^145
+141 ;;^UTILITY(U,$J,358.3,5270,1,0)
+142 ;;=^358.31IA^4^2
+143 ;;^UTILITY(U,$J,358.3,5270,1,3,0)
+144 ;;=3^Long Term (Current) Use of Oral Hypoglycemics
+145 ;;^UTILITY(U,$J,358.3,5270,1,4,0)
+146 ;;=4^Z79.84
+147 ;;^UTILITY(U,$J,358.3,5270,2)
+148 ;;=^5140432
+149 ;;^UTILITY(U,$J,358.3,5271,0)
+150 ;;=Z79.899^^34^292^146
+151 ;;^UTILITY(U,$J,358.3,5271,1,0)
+152 ;;=^358.31IA^4^2
+153 ;;^UTILITY(U,$J,358.3,5271,1,3,0)
+154 ;;=3^Long Term (Current) Use of Oth Drug Therapy
+155 ;;^UTILITY(U,$J,358.3,5271,1,4,0)
+156 ;;=4^Z79.899
+157 ;;^UTILITY(U,$J,358.3,5271,2)
+158 ;;=^5063343
+159 ;;^UTILITY(U,$J,358.3,5272,0)
+160 ;;=Z79.01^^34^292^140
+161 ;;^UTILITY(U,$J,358.3,5272,1,0)
+162 ;;=^358.31IA^4^2
+163 ;;^UTILITY(U,$J,358.3,5272,1,3,0)
+164 ;;=3^Long Term (Current) Use of Anticoagulants
+165 ;;^UTILITY(U,$J,358.3,5272,1,4,0)
+166 ;;=4^Z79.01
+167 ;;^UTILITY(U,$J,358.3,5272,2)
+168 ;;=^5063330
+169 ;;^UTILITY(U,$J,358.3,5273,0)
+170 ;;=Z79.02^^34^292^141
+171 ;;^UTILITY(U,$J,358.3,5273,1,0)
+172 ;;=^358.31IA^4^2
+173 ;;^UTILITY(U,$J,358.3,5273,1,3,0)
+174 ;;=3^Long Term (Current) Use of Antithrombotics/Antiplatelets
+175 ;;^UTILITY(U,$J,358.3,5273,1,4,0)
+176 ;;=4^Z79.02
+177 ;;^UTILITY(U,$J,358.3,5273,2)
+178 ;;=^5063331
+179 ;;^UTILITY(U,$J,358.3,5274,0)
+180 ;;=Z79.82^^34^292^142
+181 ;;^UTILITY(U,$J,358.3,5274,1,0)
+182 ;;=^358.31IA^4^2
+183 ;;^UTILITY(U,$J,358.3,5274,1,3,0)
+184 ;;=3^Long Term (Current) Use of Aspirin
+185 ;;^UTILITY(U,$J,358.3,5274,1,4,0)
+186 ;;=4^Z79.82
+187 ;;^UTILITY(U,$J,358.3,5274,2)
+188 ;;=^5063340
+189 ;;^UTILITY(U,$J,358.3,5275,0)
+190 ;;=Z79.51^^34^292^143
+191 ;;^UTILITY(U,$J,358.3,5275,1,0)
+192 ;;=^358.31IA^4^2
+193 ;;^UTILITY(U,$J,358.3,5275,1,3,0)
+194 ;;=3^Long Term (Current) Use of Inhaled Steroids
+195 ;;^UTILITY(U,$J,358.3,5275,1,4,0)
+196 ;;=4^Z79.51
+197 ;;^UTILITY(U,$J,358.3,5275,2)
+198 ;;=^5063335
+199 ;;^UTILITY(U,$J,358.3,5276,0)
+200 ;;=Z79.52^^34^292^147
+201 ;;^UTILITY(U,$J,358.3,5276,1,0)
+202 ;;=^358.31IA^4^2
+203 ;;^UTILITY(U,$J,358.3,5276,1,3,0)
+204 ;;=3^Long Term (Current) Use of Systemic Steroids
+205 ;;^UTILITY(U,$J,358.3,5276,1,4,0)
+206 ;;=4^Z79.52
+207 ;;^UTILITY(U,$J,358.3,5276,2)
+208 ;;=^5063336
+209 ;;^UTILITY(U,$J,358.3,5277,0)
+210 ;;=E22.8^^34^292^200
+211 ;;^UTILITY(U,$J,358.3,5277,1,0)
+212 ;;=^358.31IA^4^2
+213 ;;^UTILITY(U,$J,358.3,5277,1,3,0)
+214 ;;=3^Pituitary Hyperfunction,Other
+215 ;;^UTILITY(U,$J,358.3,5277,1,4,0)
+216 ;;=4^E22.8
+217 ;;^UTILITY(U,$J,358.3,5277,2)
+218 ;;=^5002719
+219 ;;^UTILITY(U,$J,358.3,5278,0)
+220 ;;=E22.2^^34^292^221
+221 ;;^UTILITY(U,$J,358.3,5278,1,0)
+222 ;;=^358.31IA^4^2
+223 ;;^UTILITY(U,$J,358.3,5278,1,3,0)
+224 ;;=3^SIADH
+225 ;;^UTILITY(U,$J,358.3,5278,1,4,0)
+226 ;;=4^E22.2
+227 ;;^UTILITY(U,$J,358.3,5278,2)
+228 ;;=^5002718
+229 ;;^UTILITY(U,$J,358.3,5279,0)
+230 ;;=T45.1X5A^^34^292^20
+231 ;;^UTILITY(U,$J,358.3,5279,1,0)
+232 ;;=^358.31IA^4^2
+233 ;;^UTILITY(U,$J,358.3,5279,1,3,0)
+234 ;;=3^Adverse Effect,Antineoplastic/Immunosuppressive,Init Enctr
+235 ;;^UTILITY(U,$J,358.3,5279,1,4,0)
+236 ;;=4^T45.1X5A
+237 ;;^UTILITY(U,$J,358.3,5279,2)
+238 ;;=^5051026
+239 ;;^UTILITY(U,$J,358.3,5280,0)
+240 ;;=T45.1X5D^^34^292^21
+241 ;;^UTILITY(U,$J,358.3,5280,1,0)
+242 ;;=^358.31IA^4^2
+243 ;;^UTILITY(U,$J,358.3,5280,1,3,0)
+244 ;;=3^Adverse Effect,Antineoplastic/Immunosuppressive,Subsq
+245 ;;^UTILITY(U,$J,358.3,5280,1,4,0)
+246 ;;=4^T45.1X5D
+247 ;;^UTILITY(U,$J,358.3,5280,2)
+248 ;;=^5051027
+249 ;;^UTILITY(U,$J,358.3,5281,0)
+250 ;;=T45.1X5S^^34^292^22
+251 ;;^UTILITY(U,$J,358.3,5281,1,0)
+252 ;;=^358.31IA^4^2
+253 ;;^UTILITY(U,$J,358.3,5281,1,3,0)
+254 ;;=3^Adverse Effect,Antineoplastic/Immunosuppressive,Sequela
+255 ;;^UTILITY(U,$J,358.3,5281,1,4,0)
+256 ;;=4^T45.1X5S
+257 ;;^UTILITY(U,$J,358.3,5281,2)
+258 ;;=^5051028
+259 ;;^UTILITY(U,$J,358.3,5282,0)
+260 ;;=T46.2X5A^^34^292^17
+261 ;;^UTILITY(U,$J,358.3,5282,1,0)
+262 ;;=^358.31IA^4^2
+263 ;;^UTILITY(U,$J,358.3,5282,1,3,0)
+264 ;;=3^Adverse Effect,Antidysrhthmic,Init Encntr
+265 ;;^UTILITY(U,$J,358.3,5282,1,4,0)
+266 ;;=4^T46.2X5A
+267 ;;^UTILITY(U,$J,358.3,5282,2)
+268 ;;=^5051296
+269 ;;^UTILITY(U,$J,358.3,5283,0)
+270 ;;=T46.2X5D^^34^292^19
+271 ;;^UTILITY(U,$J,358.3,5283,1,0)
+272 ;;=^358.31IA^4^2
+273 ;;^UTILITY(U,$J,358.3,5283,1,3,0)
+274 ;;=3^Adverse Effect,Antidysrhthmic,Subsq
+275 ;;^UTILITY(U,$J,358.3,5283,1,4,0)
+276 ;;=4^T46.2X5D
+277 ;;^UTILITY(U,$J,358.3,5283,2)
+278 ;;=^5051297
+279 ;;^UTILITY(U,$J,358.3,5284,0)
+280 ;;=T46.2X5S^^34^292^18
+281 ;;^UTILITY(U,$J,358.3,5284,1,0)
+282 ;;=^358.31IA^4^2
+283 ;;^UTILITY(U,$J,358.3,5284,1,3,0)
+284 ;;=3^Adverse Effect,Antidysrhthmic,Sequela
+285 ;;^UTILITY(U,$J,358.3,5284,1,4,0)
+286 ;;=4^T46.2X5S
+287 ;;^UTILITY(U,$J,358.3,5284,2)
+288 ;;=^5051298
+289 ;;^UTILITY(U,$J,358.3,5285,0)
+290 ;;=N91.0^^34^292^24
+291 ;;^UTILITY(U,$J,358.3,5285,1,0)
+292 ;;=^358.31IA^4^2
+293 ;;^UTILITY(U,$J,358.3,5285,1,3,0)
+294 ;;=3^Amenorrhea,Primary
+295 ;;^UTILITY(U,$J,358.3,5285,1,4,0)
+296 ;;=4^N91.0
+297 ;;^UTILITY(U,$J,358.3,5285,2)
+298 ;;=^5015902
+299 ;;^UTILITY(U,$J,358.3,5286,0)
+300 ;;=N91.1^^34^292^25
+301 ;;^UTILITY(U,$J,358.3,5286,1,0)
+302 ;;=^358.31IA^4^2
+303 ;;^UTILITY(U,$J,358.3,5286,1,3,0)
+304 ;;=3^Amenorrhea,Secondary
+305 ;;^UTILITY(U,$J,358.3,5286,1,4,0)
+306 ;;=4^N91.1
+307 ;;^UTILITY(U,$J,358.3,5286,2)
+308 ;;=^5015903
+309 ;;^UTILITY(U,$J,358.3,5287,0)
+310 ;;=N91.2^^34^292^26
+311 ;;^UTILITY(U,$J,358.3,5287,1,0)
+312 ;;=^358.31IA^4^2
+313 ;;^UTILITY(U,$J,358.3,5287,1,3,0)
+314 ;;=3^Amenorrhea,Unspec
+315 ;;^UTILITY(U,$J,358.3,5287,1,4,0)
+316 ;;=4^N91.2
+317 ;;^UTILITY(U,$J,358.3,5287,2)
+318 ;;=^5015904
+319 ;;^UTILITY(U,$J,358.3,5288,0)
+320 ;;=Z98.84^^34^292^33
+321 ;;^UTILITY(U,$J,358.3,5288,1,0)
+322 ;;=^358.31IA^4^2
+323 ;;^UTILITY(U,$J,358.3,5288,1,3,0)
+324 ;;=3^Bariatric Surgery Status
+325 ;;^UTILITY(U,$J,358.3,5288,1,4,0)
+326 ;;=4^Z98.84
+327 ;;^UTILITY(U,$J,358.3,5288,2)
+328 ;;=^5063749
+329 ;;^UTILITY(U,$J,358.3,5289,0)
+330 ;;=N18.6^^34^292^50
+331 ;;^UTILITY(U,$J,358.3,5289,1,0)
+332 ;;=^358.31IA^4^2
+333 ;;^UTILITY(U,$J,358.3,5289,1,3,0)
+334 ;;=3^CKD,Stage 6 (ESRD)
+335 ;;^UTILITY(U,$J,358.3,5289,1,4,0)
+336 ;;=4^N18.6
+337 ;;^UTILITY(U,$J,358.3,5289,2)
+338 ;;=^303986
+339 ;;^UTILITY(U,$J,358.3,5290,0)
+340 ;;=E25.0^^34^292^11
+341 ;;^UTILITY(U,$J,358.3,5290,1,0)
+342 ;;=^358.31IA^4^2
+343 ;;^UTILITY(U,$J,358.3,5290,1,3,0)
+344 ;;=3^Adrenal Hyperplasia,Congenital
+345 ;;^UTILITY(U,$J,358.3,5290,1,4,0)
+346 ;;=4^E25.0
+347 ;;^UTILITY(U,$J,358.3,5290,2)
+348 ;;=^5002732
+349 ;;^UTILITY(U,$J,358.3,5291,0)
+350 ;;=E11.69^^34^292^67
+351 ;;^UTILITY(U,$J,358.3,5291,1,0)
+352 ;;=^358.31IA^4^2
+353 ;;^UTILITY(U,$J,358.3,5291,1,3,0)
+354 ;;=3^Diabetes Type 2 w/ Oth Specified Complication
+355 ;;^UTILITY(U,$J,358.3,5291,1,4,0)
+356 ;;=4^E11.69
+357 ;;^UTILITY(U,$J,358.3,5291,2)
+358 ;;=^5002664
+359 ;;^UTILITY(U,$J,358.3,5292,0)
+360 ;;=F64.0^^34^292^76
+361 ;;^UTILITY(U,$J,358.3,5292,1,0)
+362 ;;=^358.31IA^4^2
+363 ;;^UTILITY(U,$J,358.3,5292,1,3,0)
+364 ;;=3^Gender Dysphoria
+365 ;;^UTILITY(U,$J,358.3,5292,1,4,0)
+366 ;;=4^F64.0
+367 ;;^UTILITY(U,$J,358.3,5292,2)
+368 ;;=^121404
+369 ;;^UTILITY(U,$J,358.3,5293,0)
+370 ;;=E05.01^^34^292^78
+371 ;;^UTILITY(U,$J,358.3,5293,1,0)
+372 ;;=^358.31IA^4^2
+373 ;;^UTILITY(U,$J,358.3,5293,1,3,0)
+374 ;;=3^Graves Disease w/ Thyrotoxic Crisis/Storm
+375 ;;^UTILITY(U,$J,358.3,5293,1,4,0)
+376 ;;=4^E05.01
+377 ;;^UTILITY(U,$J,358.3,5293,2)
+378 ;;=^5002482
+379 ;;^UTILITY(U,$J,358.3,5294,0)
+380 ;;=E28.1^^34^292^100
+381 ;;^UTILITY(U,$J,358.3,5294,1,0)
+382 ;;=^358.31IA^4^2
+383 ;;^UTILITY(U,$J,358.3,5294,1,3,0)
+384 ;;=3^Hyperandrogenism
+385 ;;^UTILITY(U,$J,358.3,5294,1,4,0)
+386 ;;=4^E28.1
+387 ;;^UTILITY(U,$J,358.3,5294,2)
+388 ;;=^5002748
+389 ;;^UTILITY(U,$J,358.3,5295,0)
+390 ;;=E87.5^^34^292^103
+391 ;;^UTILITY(U,$J,358.3,5295,1,0)
+392 ;;=^358.31IA^4^2
+393 ;;^UTILITY(U,$J,358.3,5295,1,3,0)
+394 ;;=3^Hyperkalemia
+395 ;;^UTILITY(U,$J,358.3,5295,1,4,0)
+396 ;;=4^E87.5
+397 ;;^UTILITY(U,$J,358.3,5295,2)
+398 ;;=^60041
+399 ;;^UTILITY(U,$J,358.3,5296,0)
+400 ;;=I50.1^^34^292^90
+401 ;;^UTILITY(U,$J,358.3,5296,1,0)
+402 ;;=^358.31IA^4^2
+403 ;;^UTILITY(U,$J,358.3,5296,1,3,0)
+404 ;;=3^Heart Failure,Left Ventricular
+405 ;;^UTILITY(U,$J,358.3,5296,1,4,0)
+406 ;;=4^I50.1
+407 ;;^UTILITY(U,$J,358.3,5296,2)
+408 ;;=^5007238
+409 ;;^UTILITY(U,$J,358.3,5297,0)
+410 ;;=I50.21^^34^292^95
+411 ;;^UTILITY(U,$J,358.3,5297,1,0)
+412 ;;=^358.31IA^4^2
+413 ;;^UTILITY(U,$J,358.3,5297,1,3,0)
+414 ;;=3^Heart Failure,Systolic,Acute
+415 ;;^UTILITY(U,$J,358.3,5297,1,4,0)
+416 ;;=4^I50.21
+417 ;;^UTILITY(U,$J,358.3,5297,2)
+418 ;;=^5007240
+419 ;;^UTILITY(U,$J,358.3,5298,0)
+420 ;;=I50.22^^34^292^97
+421 ;;^UTILITY(U,$J,358.3,5298,1,0)
+422 ;;=^358.31IA^4^2
+423 ;;^UTILITY(U,$J,358.3,5298,1,3,0)
+424 ;;=3^Heart Failure,Systolic,Chronic
+425 ;;^UTILITY(U,$J,358.3,5298,1,4,0)
+426 ;;=4^I50.22
+427 ;;^UTILITY(U,$J,358.3,5298,2)
+428 ;;=^5007241
+429 ;;^UTILITY(U,$J,358.3,5299,0)
+430 ;;=I50.23^^34^292^96
+431 ;;^UTILITY(U,$J,358.3,5299,1,0)
+432 ;;=^358.31IA^4^2
+433 ;;^UTILITY(U,$J,358.3,5299,1,3,0)
+434 ;;=3^Heart Failure,Systolic,Acute on Chronic
+435 ;;^UTILITY(U,$J,358.3,5299,1,4,0)
+436 ;;=4^I50.23
+437 ;;^UTILITY(U,$J,358.3,5299,2)
+438 ;;=^5007242
+439 ;;^UTILITY(U,$J,358.3,5300,0)
+440 ;;=I50.31^^34^292^85
+441 ;;^UTILITY(U,$J,358.3,5300,1,0)
+442 ;;=^358.31IA^4^2
+443 ;;^UTILITY(U,$J,358.3,5300,1,3,0)
+444 ;;=3^Heart Failure,Diastolic,Acute
+445 ;;^UTILITY(U,$J,358.3,5300,1,4,0)
+446 ;;=4^I50.31
+447 ;;^UTILITY(U,$J,358.3,5300,2)
+448 ;;=^5007244
+449 ;;^UTILITY(U,$J,358.3,5301,0)
+450 ;;=I50.32^^34^292^87
+451 ;;^UTILITY(U,$J,358.3,5301,1,0)
+452 ;;=^358.31IA^4^2
+453 ;;^UTILITY(U,$J,358.3,5301,1,3,0)
+454 ;;=3^Heart Failure,Diastolic,Chronic
+455 ;;^UTILITY(U,$J,358.3,5301,1,4,0)
+456 ;;=4^I50.32
+457 ;;^UTILITY(U,$J,358.3,5301,2)
+458 ;;=^5007245
+459 ;;^UTILITY(U,$J,358.3,5302,0)
+460 ;;=I50.33^^34^292^86
+461 ;;^UTILITY(U,$J,358.3,5302,1,0)
+462 ;;=^358.31IA^4^2
+463 ;;^UTILITY(U,$J,358.3,5302,1,3,0)
+464 ;;=3^Heart Failure,Diastolic,Acute on Chronic
+465 ;;^UTILITY(U,$J,358.3,5302,1,4,0)
+466 ;;=4^I50.33
+467 ;;^UTILITY(U,$J,358.3,5302,2)
+468 ;;=^5007246
+469 ;;^UTILITY(U,$J,358.3,5303,0)
+470 ;;=I50.41^^34^292^82
+471 ;;^UTILITY(U,$J,358.3,5303,1,0)
+472 ;;=^358.31IA^4^2
+473 ;;^UTILITY(U,$J,358.3,5303,1,3,0)
+474 ;;=3^Heart Failure,Combined,Acute
+475 ;;^UTILITY(U,$J,358.3,5303,1,4,0)
+476 ;;=4^I50.41
+477 ;;^UTILITY(U,$J,358.3,5303,2)
+478 ;;=^5007248
+479 ;;^UTILITY(U,$J,358.3,5304,0)
+480 ;;=I50.42^^34^292^84
+481 ;;^UTILITY(U,$J,358.3,5304,1,0)
+482 ;;=^358.31IA^4^2
+483 ;;^UTILITY(U,$J,358.3,5304,1,3,0)
+484 ;;=3^Heart Failure,Combined,Chronic
+485 ;;^UTILITY(U,$J,358.3,5304,1,4,0)
+486 ;;=4^I50.42
+487 ;;^UTILITY(U,$J,358.3,5304,2)
+488 ;;=^5007249
+489 ;;^UTILITY(U,$J,358.3,5305,0)
+490 ;;=I50.43^^34^292^83
+491 ;;^UTILITY(U,$J,358.3,5305,1,0)
+492 ;;=^358.31IA^4^2
+493 ;;^UTILITY(U,$J,358.3,5305,1,3,0)
+494 ;;=3^Heart Failure,Combined,Acute on Chronic
+495 ;;^UTILITY(U,$J,358.3,5305,1,4,0)
+496 ;;=4^I50.43
+497 ;;^UTILITY(U,$J,358.3,5305,2)
+498 ;;=^5007250
+499 ;;^UTILITY(U,$J,358.3,5306,0)
+500 ;;=I50.811^^34^292^92
+501 ;;^UTILITY(U,$J,358.3,5306,1,0)
+502 ;;=^358.31IA^4^2
+503 ;;^UTILITY(U,$J,358.3,5306,1,3,0)
+504 ;;=3^Heart Failure,Right,Acute
+505 ;;^UTILITY(U,$J,358.3,5306,1,4,0)
+506 ;;=4^I50.811
+507 ;;^UTILITY(U,$J,358.3,5306,2)
+508 ;;=^5151385
+509 ;;^UTILITY(U,$J,358.3,5307,0)
+510 ;;=I50.812^^34^292^94
+511 ;;^UTILITY(U,$J,358.3,5307,1,0)
+512 ;;=^358.31IA^4^2
+513 ;;^UTILITY(U,$J,358.3,5307,1,3,0)
+514 ;;=3^Heart Failure,Right,Chronic
+515 ;;^UTILITY(U,$J,358.3,5307,1,4,0)
+516 ;;=4^I50.812
+517 ;;^UTILITY(U,$J,358.3,5307,2)
+518 ;;=^5151386
+519 ;;^UTILITY(U,$J,358.3,5308,0)
+520 ;;=I50.813^^34^292^93
+521 ;;^UTILITY(U,$J,358.3,5308,1,0)
+522 ;;=^358.31IA^4^2
+523 ;;^UTILITY(U,$J,358.3,5308,1,3,0)
+524 ;;=3^Heart Failure,Right,Acute on Chronic
+525 ;;^UTILITY(U,$J,358.3,5308,1,4,0)
+526 ;;=4^I50.813
+527 ;;^UTILITY(U,$J,358.3,5308,2)
+528 ;;=^5151387
+529 ;;^UTILITY(U,$J,358.3,5309,0)
+530 ;;=I50.814^^34^292^91
+531 ;;^UTILITY(U,$J,358.3,5309,1,0)
+532 ;;=^358.31IA^4^2
+533 ;;^UTILITY(U,$J,358.3,5309,1,3,0)
+534 ;;=3^Heart Failure,Right due to Left
+535 ;;^UTILITY(U,$J,358.3,5309,1,4,0)
+536 ;;=4^I50.814
+537 ;;^UTILITY(U,$J,358.3,5309,2)
+538 ;;=^5151388
+539 ;;^UTILITY(U,$J,358.3,5310,0)
+540 ;;=I50.82^^34^292^81
+541 ;;^UTILITY(U,$J,358.3,5310,1,0)
+542 ;;=^358.31IA^4^2
+543 ;;^UTILITY(U,$J,358.3,5310,1,3,0)
+544 ;;=3^Heart Failure,Biventricular
+545 ;;^UTILITY(U,$J,358.3,5310,1,4,0)
+546 ;;=4^I50.82
+547 ;;^UTILITY(U,$J,358.3,5310,2)
+548 ;;=^5151389
+549 ;;^UTILITY(U,$J,358.3,5311,0)
+550 ;;=I50.83^^34^292^89
+551 ;;^UTILITY(U,$J,358.3,5311,1,0)
+552 ;;=^358.31IA^4^2
+553 ;;^UTILITY(U,$J,358.3,5311,1,3,0)
+554 ;;=3^Heart Failure,High Output
+555 ;;^UTILITY(U,$J,358.3,5311,1,4,0)
+556 ;;=4^I50.83
+557 ;;^UTILITY(U,$J,358.3,5311,2)
+558 ;;=^5151390
+559 ;;^UTILITY(U,$J,358.3,5312,0)
+560 ;;=I50.84^^34^292^88
+561 ;;^UTILITY(U,$J,358.3,5312,1,0)
+562 ;;=^358.31IA^4^2
+563 ;;^UTILITY(U,$J,358.3,5312,1,3,0)
+564 ;;=3^Heart Failure,End Stage
+565 ;;^UTILITY(U,$J,358.3,5312,1,4,0)
+566 ;;=4^I50.84
+567 ;;^UTILITY(U,$J,358.3,5312,2)
+568 ;;=^5151391
+569 ;;^UTILITY(U,$J,358.3,5313,0)
+570 ;;=L68.0^^34^292^98
+571 ;;^UTILITY(U,$J,358.3,5313,1,0)
+572 ;;=^358.31IA^4^2
+573 ;;^UTILITY(U,$J,358.3,5313,1,3,0)
+574 ;;=3^Hirsutism
+575 ;;^UTILITY(U,$J,358.3,5313,1,4,0)
+576 ;;=4^L68.0
+577 ;;^UTILITY(U,$J,358.3,5313,2)
+578 ;;=^5009262
+579 ;;^UTILITY(U,$J,358.3,5314,0)
+580 ;;=I11.0^^34^292^117
+581 ;;^UTILITY(U,$J,358.3,5314,1,0)
+582 ;;=^358.31IA^4^2
+583 ;;^UTILITY(U,$J,358.3,5314,1,3,0)
+584 ;;=3^Hypertensive Hrt Disease w/ Hrt Failure
+585 ;;^UTILITY(U,$J,358.3,5314,1,4,0)
+586 ;;=4^I11.0
+587 ;;^UTILITY(U,$J,358.3,5314,2)
+588 ;;=^5007063
+589 ;;^UTILITY(U,$J,358.3,5315,0)
+590 ;;=I11.9^^34^292^118
+591 ;;^UTILITY(U,$J,358.3,5315,1,0)
+592 ;;=^358.31IA^4^2
+593 ;;^UTILITY(U,$J,358.3,5315,1,3,0)
+594 ;;=3^Hypertensive Hrt Disease w/o Hrt Failure
+595 ;;^UTILITY(U,$J,358.3,5315,1,4,0)
+596 ;;=4^I11.9
+597 ;;^UTILITY(U,$J,358.3,5315,2)
+598 ;;=^5007064
+599 ;;^UTILITY(U,$J,358.3,5316,0)
+600 ;;=I12.0^^34^292^120
+601 ;;^UTILITY(U,$J,358.3,5316,1,0)
+602 ;;=^358.31IA^4^2
+603 ;;^UTILITY(U,$J,358.3,5316,1,3,0)
+604 ;;=3^Hypertensive Kidney Disease w/ CKD5/ESRD
+605 ;;^UTILITY(U,$J,358.3,5316,1,4,0)
+606 ;;=4^I12.0
+607 ;;^UTILITY(U,$J,358.3,5316,2)
+608 ;;=^5007065
+609 ;;^UTILITY(U,$J,358.3,5317,0)
+610 ;;=I12.9^^34^292^119
+611 ;;^UTILITY(U,$J,358.3,5317,1,0)
+612 ;;=^358.31IA^4^2
+613 ;;^UTILITY(U,$J,358.3,5317,1,3,0)
+614 ;;=3^Hypertensive Kidney Disease w/ CKD1-CKD4
+615 ;;^UTILITY(U,$J,358.3,5317,1,4,0)
+616 ;;=4^I12.9
+617 ;;^UTILITY(U,$J,358.3,5317,2)
+618 ;;=^5007066
+619 ;;^UTILITY(U,$J,358.3,5318,0)
+620 ;;=I13.0^^34^292^113
+621 ;;^UTILITY(U,$J,358.3,5318,1,0)
+622 ;;=^358.31IA^4^2
+623 ;;^UTILITY(U,$J,358.3,5318,1,3,0)
+624 ;;=3^Hypertensive Hrt & Kidney Disease w/ CKD1-CKD4
+625 ;;^UTILITY(U,$J,358.3,5318,1,4,0)
+626 ;;=4^I13.0
+627 ;;^UTILITY(U,$J,358.3,5318,2)
+628 ;;=^5007067
+629 ;;^UTILITY(U,$J,358.3,5319,0)
+630 ;;=I13.10^^34^292^115
+631 ;;^UTILITY(U,$J,358.3,5319,1,0)
+632 ;;=^358.31IA^4^2
+633 ;;^UTILITY(U,$J,358.3,5319,1,3,0)
+634 ;;=3^Hypertensive Hrt Diseas w/o CHF w/ CKD1-CKD4
+635 ;;^UTILITY(U,$J,358.3,5319,1,4,0)
+636 ;;=4^I13.10
+637 ;;^UTILITY(U,$J,358.3,5319,2)
+638 ;;=^5007068
+639 ;;^UTILITY(U,$J,358.3,5320,0)
+640 ;;=I13.11^^34^292^116
+641 ;;^UTILITY(U,$J,358.3,5320,1,0)
+642 ;;=^358.31IA^4^2
+643 ;;^UTILITY(U,$J,358.3,5320,1,3,0)
+644 ;;=3^Hypertensive Hrt Diseas w/o CHF w/ CKD5/ESRD
+645 ;;^UTILITY(U,$J,358.3,5320,1,4,0)
+646 ;;=4^I13.11
+647 ;;^UTILITY(U,$J,358.3,5320,2)
+648 ;;=^5007069
+649 ;;^UTILITY(U,$J,358.3,5321,0)
+650 ;;=I13.2^^34^292^114
+651 ;;^UTILITY(U,$J,358.3,5321,1,0)
+652 ;;=^358.31IA^4^2
+653 ;;^UTILITY(U,$J,358.3,5321,1,3,0)
+654 ;;=3^Hypertensive Hrt & Kidney Disease w/ CKD5/ESRD
+655 ;;^UTILITY(U,$J,358.3,5321,1,4,0)
+656 ;;=4^I13.2
+657 ;;^UTILITY(U,$J,358.3,5321,2)
+658 ;;=^5007070
+659 ;;^UTILITY(U,$J,358.3,5322,0)
+660 ;;=E87.6^^34^292^126
+661 ;;^UTILITY(U,$J,358.3,5322,1,0)
+662 ;;=^358.31IA^4^2
+663 ;;^UTILITY(U,$J,358.3,5322,1,3,0)
+664 ;;=3^Hypokalemia
+665 ;;^UTILITY(U,$J,358.3,5322,1,4,0)
+666 ;;=4^E87.6
+667 ;;^UTILITY(U,$J,358.3,5322,2)
+668 ;;=^60610
+669 ;;^UTILITY(U,$J,358.3,5323,0)
+670 ;;=E87.1^^34^292^127
+671 ;;^UTILITY(U,$J,358.3,5323,1,0)
+672 ;;=^358.31IA^4^2
+673 ;;^UTILITY(U,$J,358.3,5323,1,3,0)
+674 ;;=3^Hyponatremia
+675 ;;^UTILITY(U,$J,358.3,5323,1,4,0)
+676 ;;=4^E87.1
+677 ;;^UTILITY(U,$J,358.3,5323,2)
+678 ;;=^5003019
+679 ;;^UTILITY(U,$J,358.3,5324,0)
+680 ;;=E23.6^^34^292^128
+681 ;;^UTILITY(U,$J,358.3,5324,1,0)
+682 ;;=^358.31IA^4^2
+683 ;;^UTILITY(U,$J,358.3,5324,1,3,0)
+684 ;;=3^Hypophysitis
+685 ;;^UTILITY(U,$J,358.3,5324,1,4,0)
+686 ;;=4^E23.6
+687 ;;^UTILITY(U,$J,358.3,5324,2)
+688 ;;=^5002723
+689 ;;^UTILITY(U,$J,358.3,5325,0)
+690 ;;=Q98.0^^34^292^136
+691 ;;^UTILITY(U,$J,358.3,5325,1,0)
+692 ;;=^358.31IA^4^2
+693 ;;^UTILITY(U,$J,358.3,5325,1,3,0)
+694 ;;=3^Klinefelter Syndrome,Karyotype 47,XXY
+695 ;;^UTILITY(U,$J,358.3,5325,1,4,0)
+696 ;;=4^Q98.0
+697 ;;^UTILITY(U,$J,358.3,5325,2)
+698 ;;=^5019149
+699 ;;^UTILITY(U,$J,358.3,5326,0)
+700 ;;=Q98.1^^34^292^137
